Adipose dervied stem cell therapy - Pell Bio-Med Technology
Alternative Names: Gene-modified ADSCLatest Information Update: 28 Apr 2022
At a glance
- Originator Pell Bio-Med Technology
- Class Antineoplastics; Gene therapies; Immunotherapies; Mesenchymal stem cell therapies; Pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours; Unspecified
Most Recent Events
- 21 Apr 2022 Preclinical trials in Unspecified in Taiwan (Parenteral), prior to April 2022 (Pell Bio-Med Technology pipeline, April 2022)
- 21 Apr 2022 Preclinical trials in Solid tumours in Taiwan (Parenteral), prior to April 2022 (Pell Bio-Med Technology pipeline, April 2022)